Arm1: DUR-928 treatment for moderate alcoholic hepatitis for Alcoholic Hepatitis

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
University of Louisville, Louisville, KYAlcoholic HepatitisDUR-928 (Moderate AH) - Drug
Eligibility
21 - 67
All Sexes
What conditions do you have?
Select

Study Summary

This trial is to study the safety and effects of the drug DUR-928 in patients with AH (acute hepatitis). The drug will be given intravenously in two doses, four days apart. The trial will study the effects of the drug on the liver and how the body processes it.

Eligible Conditions
  • Alcoholic Hepatitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

10 Primary · 0 Secondary · Reporting Duration: 4.5 years.

33 days.
Biomarkers of Inflammation (Interleukins): Interleukin 6 and Interleukin 8
Biomarkers of Inflammation: C-reactive Protein
Biomarkers of liver cell death: Cytokeratin 18 (CK18)
Pharmacodynamic signals of DUR-928: Liver Biochemical Biomarker "Alanine Aminotransferase"
Pharmacodynamic signals of DUR-928: Liver Biochemical Biomarker "Albumin"
Pharmacodynamic signals of DUR-928: Liver Biochemical Biomarker "Aspartate Aminotransferase"
Pharmacodynamic signals of DUR-928: Liver Biochemical Biomarker "Total Bilirubin"
Pharmacodynamic signals of DUR-928: Model for End-Stage Liver Disease [MELD]
Quality of life biomarkers: 36-item Short Form Survey (SF-36).
4.5 years.
Assessment of Treatment-Emergent Adverse Events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Arm1: DUR-928 treatment for moderate alcoholic hepatitis
1 of 2
Arm 2: DUR-928 treatment for severe alcoholic hepatitis.
1 of 2

Active Control

36 Total Participants · 2 Treatment Groups

Primary Treatment: Arm1: DUR-928 treatment for moderate alcoholic hepatitis · No Placebo Group · Phase 2

Arm1: DUR-928 treatment for moderate alcoholic hepatitis
Drug
ActiveComparator Group · 1 Intervention: DUR-928 (Moderate AH) · Intervention Types: Drug
Arm 2: DUR-928 treatment for severe alcoholic hepatitis.
Drug
ActiveComparator Group · 1 Intervention: DUR-928 (Severe AH) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4.5 years.

Who is running the clinical trial?

Craig James McClainLead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
732 Previous Clinical Trials
1,339,720 Total Patients Enrolled
Vatsalya Vatsalya, MDStudy DirectorDepartment of Medicine, University of Louisville
Craig J McClain, M.D.Principal InvestigatorDepartment of Medicine, University of Louisville
Vatsalya Vatsalya, M.D.Study DirectorDepartment of Medicine, University of Louisville

Eligibility Criteria

Age 21 - 67 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Are there any harmful side effects to taking Arm1: DUR-928 for moderate alcoholic hepatitis?

"Arm1: DUR-928 has been studied in Phase 2 trials, so while there is some evidence indicating it is safe, none of the data collected suggests that it is an effective treatment for moderate alcoholic hepatitis." - Anonymous Online Contributor

Unverified Answer

Are participants being recruited for this experiment currently?

"Yes, this study is still recruiting patients according to the latest update on clinicaltrials.gov from November 8th, 2022. The trial was first posted June 1st, 2021 and is looking for a total of 36 participants at 1 site." - Anonymous Online Contributor

Unverified Answer

How can I become a participant in this clinical trial?

"This study is investigating the treatment of hepatitis A in patients aged 21-67. To qualify, potential participants must only suffer from hepatitis A. The recruitment goal for this clinical trial is 36 individuals." - Anonymous Online Contributor

Unverified Answer

How large is the sample size for this clinical experiment?

"That is correct. According to the most recent update, this clinical trial which was first posted on 6/1/2021 is admitting 36 patients from 1 site." - Anonymous Online Contributor

Unverified Answer

If a patient is not yet 55 years old, are they still eligible for this particular research program?

"To be eligible for this clinical trial, patients must fall within the age range of 21 to 67 years old." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.